$SNSS Now, SNSS officially is a preclinical biotech company with one molecule. If you want to bet on SNS-510 (PDK1 inhibitor), buy this in the last quarter 2020, not now. So this is why I think hedge funds are selling for now... Conclusion: the company is so rude to its investors even to tutes. What is funny here (or not), they removed Vecabrutinib from overview section in investors page!
  • 2
2 Likes